Research Notes: High-dose Stereotactic Body Radiotherapy Effective, Quick for Localized Prostate Cancer

In a study presented at the annual meeting of the American Society of Radiation Oncology, researchers found that men with organ-confined prostate cancer can be treated successfully with stereotactic body radiation therapy. The five-year, multi-center study evaluated low-risk, intermediate-risk and high-risk patients for up to four years following treatment. At the five-year mark, the relapse-free survival rate was 95 percent for low-risk patients, 90 percent for intermediate-risk patients and 80 percent for high-risk patients

Men with organ-confined prostate cancer can be treated with focused stereotactic body radiotherapy (SBRT) as outpatients in as little as five days, saving them time and money.

Centers who participated include CyberKnife Center of Tampa Bay, Tampa, Florida; Beth Israel Deaconess Medical Center, Boston; CyberKnife Centers of San Diego; San Bortolo Hospital, Vicenza, Italy; Swedish Medical Center, Seattle, WA; Georgetown University Hospital, Washington, DC, and UCLA Medical Center, Los Angeles.

To read more about the study, click here. To add to the body of clinical research examining stereotactic body radiation therapy for prostate cancer, our center recently opened a clinical trial in collaboration with the University of Pittsburgh to evaluate SBRT for low-, intermediate- and high-risk patients.

Additional prostate cancer news from around the web:

  • A recent study published by the Cancer Institute of New Jersey found that the definition of low-risk prostate cancer should not be the same for African American and Caucasian men. Read more.
  • The Wall Street Journal reports the results of a survey showing that the majority of people who receive cancer diagnoses choose to continue working after diagnosis and during treatment. Read more.
  • The New York Times reports that a new prostate cancer test could help supplement PSA testing to reduce false alarms and help determine more definitive diagnoses. Read more.